Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999;99(6):18-22.

[The efficacy of the intravenous administration of the trometamol salt of thioctic (alpha-lipoic) acid in diabetic neuropathy]

[Article in Russian]
  • PMID: 10441861
Clinical Trial

[The efficacy of the intravenous administration of the trometamol salt of thioctic (alpha-lipoic) acid in diabetic neuropathy]

[Article in Russian]
I A Strokov et al. Zh Nevrol Psikhiatr Im S S Korsakova. 1999.

Abstract

A two-central randomised single-blind placebo-controlled study was conducted to assess efficacy of intravenous administration of trometamol salt of thioctic (alpha-lipoic) acid (Thioctacid 600, "ASTA Medica", Germany) in 200 ml of physiological solution in 40 non-insulin dependent diabetic patients with symptomatic diabetic neuropathy. 10 patients of the control group received a physiological solution stained with 1% solution of riboflavin mononucleate (B2 vitamin) as placebo. Intravenous infusion was administered once daily during a period of 3 weeks. Diabetic neuropathy score was assessed at the entry as well as on days 7, 14 and 21 of therapy. Indicators of lipid peroxidation (oxidative stress)--malonic dialdehyde levels in plasma and membranes of erythrocytes. Electroneuromyography were performed. Most of the patients (29) noted symptomatic improvement after 7-10 infusions and on day 14 a significant reduction of the diabetic neuropathy score was noted in comparison to a baseline (p < 0.05). The further improvement of clinical picture had been pronounced by day 21 (p < 0.001). Improvement of symptom score was obtained in 39 patients (97.5%). The response rate in the control group was 40%. Parameters of oxidative stress and electroneuromyography improved significantly in the main group of patients, while these in placebo group remained without changes.

PubMed Disclaimer

MeSH terms